Please Wait
Applying Filters...
menu
    • menu
    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    Data Compilation
    #PharmaFlow

    Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

    Stock Recap
    #PipelineProspector

    Menu

    (2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,389Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    04/06/2025 Ami Lifesciences Private Limited
    India
    		 AMI LIFESCIENCES PRIVATE LTD 36655 BRIVARACETAM 2022-01-08 Active II N/A
    04/06/2025 Chunghwa Chemical Synthesis & Biotech
    Taiwan
    		 CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD 41491 BRIVARACETAM 2025-03-31 Active II N/A